All News

pssfing.jpg

New Treatments for Systemic Sclerosis

d EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.

Read Article
psA.fil_.Hands_.jpg

Camels and psoriatic arthritis - a new treatment link

d Antoni Chan, MD, PhD

I am a big fan of animals and wildlife. Whenever I can, I try to wander outdoors to look for our friends big and small in the animal kingdom. If it rains, as often it does in the UK, the latest edition of Planet Earth will do. So, I was naturally attracted to the presentation by Professor Iain McInnes from the University of Glasgow, oral presentation OP0195 at #EULAR2024 where the link between camels and psoriatic arthritis was made.

Read Article
LBP_0.jpg

Achieving drug-free remission in axSpA

d EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.

Read Article
puzzle.RA_.jpg

Difficult-to-treat RA: are we any closer to predicting who is at risk?

d Mrinalini Dey, MD

It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.

Read Article
EULAR 2024 - Day 1 Report https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8

Links:

Dr. John Cush RheumNow ( View Tweet)
Is Izokibep the new kid on the block in PsA? ➡️ IL-17A inhibitor ➡️ Complete resolution of enthesitis at 16w ➡️ Overall good safety data LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
EULAR OP0041 (2024) COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1 Is it safe? looks it, no serious AES, 6mo follow up Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab Does it work? will have to wait for Phase 2 Somehow bold knowing TCZ did not work in hand OA AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1 Is it safe? looks it, no serious AES, 6mo follow up Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab Does it work? will have to wait for Phase 2 Somehow bold knowing TCZ did not work in hand OA AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s. This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr

Links:

David Liew drdavidliew ( View Tweet)
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
EULAR guidelines for screening for TB in rheumatic disease patients #EULAR2024 https://t.co/jaixl8lGkY

Links:

Jilaine Bolek Berquist BolekBerqui ( View Tweet)
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Maintenance of remission in GPA/MPA. RTX for 48 months sounds good to me. #EULAR2024 https://t.co/5YGwOHhCuX

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.